The metabolic syndrome, also known as the cardiometabolic syndrome (CMS), is a state of metabolic and vascular dysregulation that is associated with activation of the renin-angiotensin-aldosterone system (RAAS). Clinical components of the CMS include central or visceral obesity, hypertension (HTN), dyslipidemia, insulin resistance/hyperinsulinemia, and microalbuminuria that collectively convey increases in oxidative stress, inflammation, and subsequent endothelial dysfunction. The cardio-renal inflammation and oxidative stress enhanced in the CMS increases the risk for cardiovascular disease (CVD) and renal disease end-points such as stroke, congestive heart failure, and chronic kidney disease (CKD). The development of proteinuria is known to herald progressive kidney disease (e.g. CKD) and both are now well accepted as CVD risk factors. Evidence suggests a role for visceral obesity, insulin resistance/hyperinsulinemia, HTN, and other components of the CMS lead to an increased risk for proteinuria and progressive loss of renal function. Intervention with agents that block the RAAS (e.g. ACE inhibitors and Angiotensin type 1 receptor blockers) have been shown to reduce proteinuria, CKD progression, and CVD events. Herein, we will examine the relationship between RAAS intervention and reductions in CKD and CVD events.
Alexander, C.M. et al. [2003] NCEP-defined metabolic syndrome, diabetes, and prevalence
2.
of coronary heart disease among NHANES III participants age 50 years and older . Diabetes52(5): 1210—1214.
3.
Aha [2004] American Heart Association. Heart Disease and Stroke Statistics — 2005 Update. Dallas, Tex: American Heart Association.
4.
Anderson, E.A. et al. [1991] Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest87: 2246—2252.
5.
Assmann, G. and Schulte, H. [1988] The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease.
6.
Am Heart J116: 1713—1724.
7.
Basu, S. et al. [1994] Lipomatous hypertrophy of the interatrial septum. Cardiovasc Surg2: 229—231.
8.
Berne, C. et al. [1992] The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetologia35: 873—879.
9.
Bharati, S. and Lev, M. [1995] Cardiac conduction system involvement in sudden death of obese young people. Am Heart J129: 273—281.
10.
Bjorntorp, P. and Rosmond, R. [2000] Neuroendocrine abnormalities in visceral obesity . Int J Obes Relat Metab Disord24(Suppl 2): S80—85.
11.
Brenner, B.M. et al. [2001] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med345: 861—869.
12.
Castro, J.P. et al. [2003] Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep5: 393—401.
13.
Ceconi, C. et al. [2007] ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res73(1): 237—246.
14.
Chen, J. et al. [2003] Insulin resistance and risk for chronic kidney disease in nondiabetice US adults. J Am Soc Nephrol14: 469—477.
15.
Chen, J. et al. [2004] The Metabolic Syndrome and Chronic Kidney Disease in US Adults. Annals of Internal Medicine140(3): 167—175.
16.
DeFronzo, R.A. [1981] The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia21: 165—171.
17.
DeFronzo, R.A. et al. [1975] The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest55: 845—855.
18.
DeFronzo, R.A. and Ferrannini, E. [1991] Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care14: 173—194.
19.
Duflou, J. et al. [1995] Sudden death as a result of heart disease in morbid obesity. Am Heart J130: 306—313.
20.
El-Atat, F.A. et al. [2004] Diabetes, Hypertension and cardiovascular derangements: Update on the pathophysiology and management. Curr Hypertens Rep6: 215—223.
21.
El-Atat, F.A. et al. [2004] The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol15(11): 2816—2827.
22.
Engeli, S. and Sharma, A.M. [2001] The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med79: 21—29.
23.
Engeli, S. and Sharma, A.M. [2002] Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol17: 355—359.
24.
Fox, K.M. [2003] EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362: 782—788.
25.
Frohlich, E.D. et al. [1983] The problem of obesity and hypertension . Hypertension5: I1171—78.
26.
Gerstein, H.C. et al. [2001] Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA286(4): 421—426.
27.
Gerstein, H.C. et al. [2000] Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet355: 253—259.
28.
Goodfriend, T.L. et al. [1998] Aldosterone in obesity. Endocr Res24: 789—796.
29.
Goodfriend, T.L. et al. [1999] Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids60: 401—405.
30.
Govindarajan, G. et al. Obesity and Hypertension: A Clinical Update. In eds, Ray R, Schiffrin E, and Sowers JR. [2006] Molecular Mechanisms in Hypertension. Taylor and Francis Pub, London, 397—406.
31.
Granger, J.P. et al. [1994] Abnormal pressure natriuresis in the dog model of obesity-induced hypertension. Hypertension23: 18—11.
32.
Hall, J.E. [1997] Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens10: 49S—55S.
33.
Hall, J.E. et al. [1993] Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension22: 292—299.
34.
Henegar, J.R. et al. [2001] Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol12: 1211—1217.
35.
Hillege, H.L. et al. [2002] Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation106: 1777.
36.
Hoehner, C.M. et al. [2002] Association of the insulin resistance syndrome and microalbuminuria among non-diabetic native Americans. The Inter-Tribal HeartProject. J Am Soc Nephrol13: 1626—1634.
37.
Hsu, C.-Y. [2002] Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. Curr Opin Nephrol Hypertension11: 267—272.
38.
Hunt, K.J. et al. [2004] National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation110(10): 1251—1257.
39.
Isomaa, B. et al. [2001] Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care24(4): 683—689.
40.
Jacobs, D.B. et al. [1993] Effects of weight reduction on cellular cation metabolism and vascular resistance. Hypertension21: 308—314.
41.
Kambham, N. et al. [2001] Obesity-related glomerulopathy: an emerging epidemic. Kidney Int59: 1498—509.
42.
K/DOQI Clinical Practive Guidelines for chronic kidney disease: evaluation, classification, and stratification. [2002] Kidney Disease Outcome Quality Initiative. Am J Kidney Dis39: S1—246.
43.
Kenchaiah, S. et al. [2002] Obesity and the risk of heart failure. N Engl J Med347: 305—313.
44.
Kincaid-Smith, P. [2004] Hypothesis: obesity and the insulin resistance syndorme play a major role in end-stage renal failure attibuted to hypertension and labell “hypertensive nephrosclerosis”. J Hypertension22: 1051—1055.
45.
Klausen, K. et al. [2004] Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation110: 32.
46.
Kurella, M. et al. [2005] Metabolic syndrome and the risk for chornic kidney disease among nondiabetic adults. The J Am Soc Nephrol16: 2134—2140.
47.
Kuusisto, J. et al. [1995] Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation90: 831.
48.
Lakka, H.M. et al. [2002] The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA288(21): 2709—2716.
49.
Lewis, E.J. et al. [2001] Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med345(12): 851—860.
50.
Licata, G. et al. [1990] Hypertension in obese subjects: distinct hypertensive subgroup. J Hum Hypertens4: 37—41.
51.
Lip, G.Y. et al. [1994] Hypertension and the heart. Br Med Bull50: 299—321.
52.
Malik, S. et al. [2004] Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation110(10): 1245—1250.
53.
Mangrum, A. and Bakris, G.L. [1997] Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications11: 352—357.
54.
Massiera, F. et al. [2001] Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology142: 5220—5225.
55.
McFarlane, S.I. et al. [2001] Insulin resistance and cardiovascular disease . J Clin Endocrinol Metab86(2): 713—718.
56.
Meigs, J.B. et al. [2001] Framingham Offspring Study: Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care24: 1403—1410.
57.
Messerli, F.H. et al. [1981] Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med141: 81—85.
58.
Messerli, F.H. et al. [1983] Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med99: 757—761.
59.
Modan, M. and Halkin, H. [1991] Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes Care14: 470—487.
60.
Mykkanen, L. et al. [1998] Microalbuminuria is associated with insulin resistance in nondiabetic subjects: The insulin resistance atherosclerosis study. Diabetes47: 793—800.
61.
Pahor, M. et al. [2000] Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care23: 888—892.
62.
Palaniappan, L. et al. [2003] Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens16: 952—958.
63.
Parving, H.H. et al. [2001] Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med345(12): 870—878.
64.
Pereira, B.J. et al. [1994] Plasma levels of Il-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int45: 890—896.
65.
Rocchini, A.P. et al. [1997] Time course of insulin resistance associated with feeding dogs a high-fat diet. Am J Physiol272: E147—154.
66.
Rocchini, A.P. et al. [1992] Forearm resistance vessel abnormalities and insulin resistance in obese adolescents. Hypertension19: 615—620.
67.
Rocchini, A.P. et al. [1990] Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension15: 861—866.
68.
Rockstroh, J.K. et al. [1992] Stress response pattern in obesity and systemic hypertension. Am J Cardiol70: 1035—1039.
69.
Roest, M. et al. [2001] Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation103: 3057.
70.
Rowe, J.W. et al. [1981] Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes30: 219—225.
71.
Schmieder, R.E. and Messerli, F.H. [1993] Does obesity influence early target organ damage in hypertensive patients?Circulation87: 1482—1488.
72.
Schorr, U. et al. [1998] Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens16: 1475—1480.
73.
Shinohora, K. et al. [2002] Insulin Resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol13: 1894—1900.
74.
Sowers, J.R. [1998] Obesity and cardiovascular disease. Clin Chem44: 1821—1825.
75.
Sowers, J.R. [2004] Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol286: H1597—H1602.
76.
Sowers, J.R. et al. [2001] Diabetes, hypertension, and cardiovascular disease: An update. Hypertension37: 1053—1059.
77.
Sowers, J.R. and Stump, C.S. [2004] Insights into the biology of diabetic vascular disease: what's new?Am J Hypertens17(11Pt2): 2S—6S.
78.
Wachtell, K. et al. [2003] Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med139: 901.
79.
Weir, M.R. et al. [1998] Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group. Am J Hypertens11: 914—920.
